Treatment of a tardive dyskinesia patient with temporomandibular disorder: A case report

Journal of Oral and Facial Pain and Headache

Volumn 24, Issue 2, 2010, Pages 212-216

  Pekkan, Gurel ^a   Kilicoglu, Alev ^a   Algin, Demet Ilhan ^a  

^a DUMLUPINAR UNIVERSITY   (Turkey)

Author keywords

Antipsychotic; Botulinum toxin type A; Clozapine; Tardive dyskinesia; Temporomandibular disorder

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; CLOZAPINE; HALOPERIDOL; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT;

AGED; ARTICLE; BRUXISM; CASE REPORT; DRUG EFFECT; DYSKINESIA; FACE PAIN; FOLLOW UP; HUMAN; MALE; MUSCLE CONTRACTION; OSTEOARTHRITIS; RECURRENT DISEASE; SCHIZOPHRENIA; TEMPOROMANDIBULAR JOINT DISORDER;

AGED; ANTIPSYCHOTIC AGENTS; BOTULINUM TOXIN TYPE A; BRUXISM; CLOZAPINE; DYSKINESIA, DRUG-INDUCED; FACIAL PAIN; FOLLOW-UP STUDIES; GABA ANTAGONISTS; HALOPERIDOL; HUMANS; MALE; MUSCLE CONTRACTION; NEUROMUSCULAR AGENTS; OSTEOARTHRITIS; RECURRENCE; SCHIZOPHRENIA; TEMPOROMANDIBULAR JOINT DISORDERS;

EID: 77954941146     PISSN: 23330384     EISSN: 23330376     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Blanchet PJ, Rompre PH, Lavigne GJ, Lamarche C. Oral Dyskinesia: A Clinical Overview. Int J Prosthodont 2005; 18:10-19
2. Soares KV, McGrath JJ. The treatment of tardive dyskinesia-a systematic review and meta-analysis. Schizophr Res 1999;39:1-18
3. Tan EK, Jankovic J. Tardive and idiopathic oromandibular dystonia: A clinical comparison. J Neurol Neurosurg Psychiatry 2000;68:186-190
4. Van Harten PN, Hovestadt A. Botulinum toxin as a treatment for tardive dyskinesia. Mov Disord 2006;21: 1276-1277
5. Osborne TE, Grace EG, Schwartz MK. Severe degenerative changes of the temporomandibular joint secondary to the effects of tardive dyskinesia: A literature review and case report. J Craniomandib Pract 1989;7:58-62
6. Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD. The natural history of tardive dystonia: A long-term follow up study of 107 cases. Brain 1998;121:2053-2066
7. Remington G. Tardive dyskinesia: Eliminated, forgotten, or overshadowed? Curr Opin Psychiatry 2007;20:131-137
8. Wyngaarden JB, Smith LH (eds). Cecil Textbook of Medicine, ed 17. Philadelphia: WB Saunders, 1985: 2075-2076
9. Smith J, Baldessarini R. Changes in prevalence, severity and recovery in tardive dyskinesias with age. Arch Gen Psychiatry 1980;37:1368-1373
10. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: Pathophysiology and mechanisma of induction. Can J Psychiatry 2005;50:541-547
11. Myers DE, Schooler NR, Zullo TG, Levin H. A retrospective study of the effects of edentulism on the severity rating of tardive dyskinesia. J Prosthet Dent 1993;69:578-581
12. Baldessarini RJ, Cole JO, Davis JM. Tardive dyskinesia: Summary of a task force report of the American Psy chi-atric Association. Am J Psychiatry 1980;137:1163-1172
13. Bassett A, Remick RA, Blasberg B. Tardive dyskinesia: An unrecognized cause of orofacial pain. Oral Surg Oral Med Oral Pathol 1986;61:570-572
14. Ford B, Greene P, Fahn S. Oral and genital tardive pain syndromes. Neurology 1994;44:2115-2119
15. Hierholzer RW. Tardive dyskinesia with complaints of pain. Am J Psychiatry 1989;146:802
16. Ihde SK, Konstantinovic VS. The therapeutic use of botulinum toxin in cervical and maxillofacial conditions: An evidence-based review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;104:e1-e11
17. Margolese HC, Ferreri F. Management of conventional antipsychotic-induced tardive dyskinesia. Rev Psychiatr Neurosci 2007;32:72
18. Jeynes LC, Gauci CA. Evidence for the use of botulinum toxin in the chronic pain setting. A review of the literature. Pain Pract 2008;8:269-276
19. Rapaport A, Sadeh M, Stein D, Levine J, Sirota P, Mosheva T, et al. Botulinum toxin for the treatment of orofacial-lingual-masticatory tardive dyskinesia. Mov Disord 2000;15:352-355
20. Kanovsky P, Streitova H, Bares M, Hortova H. Treatment of facial and orolinguomandibular tardive dystonia by botulinum toxin A: Evidence of a long-lasting effect. Mov Disord 1999;14:886-888
21. Mense S. Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol 2004;251(suppl 1):I1-7
22. Castro WH, Gomez RS, Da Silva Oliveira J, Moura MD, Gomez RS. Botulinum toxin type A in the management of masseter muscle hypertrophy. J Oral Maxillofac Surg 2005;63:20-24
23. Sutcher HD, Underwood RB, Beatty RA, Sugar O. Orofacial dyskinesia-A dental dimension. J Am Med Assoc 1971;216:1459-1463
24. Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L. Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 2009;141:60-69
25. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Can J Psychiatry 2005;50:703-714